항암버섯(차가버섯, 영지버섯) - 베타글루칸의 항암효과

[문형철]

BEYOND REASON

버섯, yeasts(효모), algae(녹조류), oat(귀리. )등에 많이 들어있는 베타 글루칸은 식균작용(phagocytosis), 인터루킨 2생성, 항체 분비, 암억제 등의 효과가 있음. 

버섯의 항암효과가 높다고 알려진 것은 바로 우리 몸의 면역활성을 높여주는 핵심성분인 베타글루칸 때문. 베타글루칸은 우리나라에서는 혈관 건강에 유익한 성분으로 널리 알려져 있으나, 일본에서는 항암 성분으로 더 유명함. 실제로 일본의 병원에서는 버섯에서 얻은 베타글루칸이 주성분인 항암제를 30년 전부터 사용. 크레스틴(구름버섯 추출물), 렌티난(표고 추출물), 시조필란(치마버섯 추출물)이 일본정부의 공식허가를 받은 항암제이다. 베타글루칸이 주성분인 ‘버섯 항암제’는 암세포를 직접 죽이지는 않고, 암환자의 면역력을 높여 암세포의 활동을 억제한다. 자연살해(NK)세포, T세포 등 면역기능과 관련된 세포의 수와 활성을 높여 주는 일종의 면역요법제이다. 

Glucans and Cancer: Comparison of Commercially Available β-glucans – Part IV

1. VACLAV VETVICKA⇑ and 
2. JANA VETVICKOVA

+Author Affiliations

1. Department of Pathology, University of Louisville, Louisville, KY, U.S.A.

1. Correspondence to: Vaclav Vetvicka, Department of Pathology, University of Louisville, 511 S. Floyd, Louisville, KY 40202, U.S.A. Tel: 502-852-1612, e-mail: Vaclav.vetvicka@louisville.edu

 

Next Section

Abstract

Background/Aim: β-Glucans are well-established immunomodulators with strong effects across all immune reactions. Due to the extensive amount of studies, glucans are steadily progressing from a non-specific immunomodulator to a licensed drug. However, direct comparisons of higher numbers of different glucans are rare. 

Materials and Methods: In this study, we used 16 different glucans isolated from yeasts, mushroom, algae, and oat and compared their effects on phagocytosis, IL-2 production, antibody secretion, and inhibition of three experimental cancer models. 

Results: Our results showed significant differences among tested glucans, showing that despite the fact that glucans in general have strong stimulating effects on most aspects of the immune system, it is necessary to choose the right glucan. 

Conclusion: Based on our studies, we can conclude that highly purified and active glucans have significant pleiotropic effects.

• Glucan
 
• cancer
 
• phagocytosis
 
• IL-2
 
• yeasts
 
• mushroom

β-1,3-D-glucans (hereafter referred to as “glucans”) form part of a group of natural biologically-active compounds generally called “biological response modifiers.” Chemically, they are heterogeneous nonstarch polysaccharides, which form structural compounds of the cell wall of some microorganisms including yeast, algae, protists, mushrooms, and grain. Generally, the term glucan is used as a chemical name of glucose polymer and represents a group of chemically heterogeneous carbohydrates. Typically, β-glucans form a linear backbone with 1-3 β-glycosidic bonds but vary with respect to molecular mass, solubility, viscosity, branching structure, and gelation properties. Insoluble β-glucans fibers consist of β-(1,3/1,4)-D-linked glucose units, whereas the soluble viscous fiber consist of β-(1,3)/1,6)-D-linked glucose.

After more than 45 years of intensive research, biological effects of glucans are well-established. Various studies definitively show that glucans represent important substances exerting strong immunomodulatory properties and may be included, among other substances, to act through an organism's own biological response mechanisms (1). Among the well-studied effects of β-glucans, we can mention stimulation of both humoral and cellular immunity (1), metabolic control of diabetes (2), stimulation of wound healing (3), stress reduction (4), attenuation of chronic fatigue syndrome (5), lowering cholesterol levels (6), and inhibition of cancer (7). Recently, glucan was successfully used as part of a vaccine for high-risk neuroblastoma (8). In addition, a series of clinical studies showed strong effects on the treatment of children with chronic respiratory problems (9, 10). In Japan, glucan has been widely used, for over 30 years, in the treatment of gastrointestinal cancer (11).

Despite over 20,000 scientific studies, the results are still not fully compatible, with many individual glucans differing in characteristics, such as molecular weight, branching, solubility, and source, it is difficult to unify the described effects. The problem of diverse data can be solved only by comparative studies. However, scientific reports directly comparing individual glucans are still limited (12-16). This led us to the current comparative review of 16 different commercially available glucans.

Previous SectionNext Section

Materials and Methods

Animals. Female, 8-week-old BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All animal work was done according to the University of Louisville IACUC protocol. Animals were sacrificed by CO₂ asphyxiation followed by cervical dislocation.

Materials. All glucans were either donated or purchased from the manufacturers or distributors as shown in Table I. Ovalbumin, polymyxin B, cyclophosphamide, and Wright stain were purchase from Sigma (St. Louis, MO, USA).

Cell lines. Murine melanoma B16 cell line (ATCC, Manassas, VA, USA), Lewis lung carcinoma cells (obtained from Dr. G. Ross, University of Louisville, Louisville, KY, USA), and BALB/c mouse-derived mammary tumor cell line Ptas64 (generously provided by Dr. Wei-Zen Wei of the Michigan Cancer Foundation, Wayne State University, Detroit, MI, USA) were maintained in culture at 37°C in a humidified atmosphere supplemented with 5% CO₂ in RPMI 1640 medium supplemented with 10% FCS.

View this table:

• In this window
 
• In a new window

Table I.

List of glucans used in this study.

Phagocytosis. Phagocytosis of synthetic polymeric microspheres was described previously (17). Briefly, 0.1 ml of peripheral blood from mice injected with various doses of glucan or PBS was incubated in vitro with 0.05 ml of 2-hydroxyethyl methacrylate particles (HEMA; 5×10⁸/ml). The tubes were incubated at 37°C for 60 min, with intermittent shaking. Smears were stained with Wright stain. The cells with three or more HEMA particles were considered positive. Mice were injected with either glucan or PBS (control). All experiments were performed in triplicate. At least 300 cells were examined in each experiment.

IL-2 secretion. Purified spleen cells (2×10⁶/ml in RPMI 1640 medium with 5% FCS) obtained from mice injected with 100 μg glucan or PBS were added into wells of a 24-well tissue culture plate. Cells were incubated for 48 h in a humidified incubator (37°C, 5% CO₂/95% air). Addition of 1 μg of Concanavalin A (Sigma, St. Louis, MO, USA) was used as a positive control. At the endpoint of incubation, supernatants were collected, filtered through 0.45 μm filters, and tested for the presence of IL-2 using a Quantikine mouse IL-2 kit (R&D Systems, Minneapolis, MN, USA).

Antibody formation. The technique was described earlier (18). Briefly, formation of antibodies was eval‎uated using ovalbumin as an antigen. Mice were injected twice (two weeks apart) with 100 μg of albumin and the serum was collected 7 days after last injection. Experimental groups received daily ip. injections of glucan. The level of specific antibodies against ovalbumin was detected by ELISA. As positive control, combination of ovalbumin and Freund's adjuvant (Sigma) was used.

Tumor inhibition in vivo. Mice were injected directly into their mammary fat pads with 1×10⁶/mouse of Ptas64 cells in PBS. The experimental treatment was begun after palpable tumors were found (approximately 14 days after injection of cells) and after mice were assigned to experimental groups. Experimental treatment was achieved by intraperitoneal injections of tested samples diluted in PBS (once/day for 14 days). After treatment, the mice were sacrificed and the tumors removed and weighed. These experiments were repeated three times with three mice per each group.

For Lewis lung carcinoma therapy, mice were injected im. with 1×10⁵ of Lewis lung carcinoma cells. Cyclophosphamide (30 mg/kg) was used ip. at day 8 after tumor application (positive control), individual substances were used from day 0 to day 14 after tumor application. The control group of mice (negative control) received ip. PBS daily. Each group held a minimum of five mice. At the conclusion of the experiment (day 14), mice were euthanized, their lungs were removed and fixed in 10% formalin, and the number of hematogenic metastases in lung tissue was estimated using a binocular lens at 8× magnification.

B16 melanoma cells were inoculated subcutaneously into shaved lateral flanks of the mice. The mice were treated by intraperitoneal injections of tested samples diluted in PBS once daily for 14 days. At the end of experiment, tumors were removed and weighed.

Previous SectionNext Section

Results

Commercial samples can contain small amounts of biologically inert fillers. Even though these fillers are not expected to influence the biological activities of the samples, it is theoretically possible that the unknown amount of fillers might affect the dose of glucan used in the study, as the 100 mg/capsule might in reality mean that the capsule weights more than 100 mg (i.e., 100 mg glucan plus fillers). Subsequent dilutions might in fact lower the used dose. To account for this possibility, we used Glucan #300, which is available as both a powder and a capsule, and compared the effects of several doses of powder and corresponding doses taken from the capsule. Figure 1 summarizes the effects on phagocytic activity and shows that the results were identical even in the lowest dose used. However, as the amount of fillers can be different from company to company, we weighed the capsule contents and calculated the amount of glucan in all subsequent experiments.

View this table:

• In this window
 
• In a new window

Table II.

Effect of glucan dose on phagocytosis.

View this table:

• In this window
 
• In a new window

Table III.

Effect of glucan supplementation on IL-2 production.

Since a lipopolysaccharide (LPS) contamination might mask the effects of any biological response modifier, we checked the LPS contamination of our samples using a 10 μg/ml solution of polymyxin B. We prepared LPS-free glucans and tested them on phagocytosis. The results were identical to those using regular samples (data not shown); therefore, we concluded that LPS is not responsible for data observed in this study.

View larger version:

• In this page
 
• In a new window

Figure 1.

Effects of addition of different doses on either glucan originated as powder (Powder) or used directly from the capsule (Capsule) on the phagocytosis of microparticles by peripheral blood neutrophils. Experiments were repeated three times, results are given as mean±SD.

Table II shows the effects of tested glucans on phagocytosis of peripheral blood neutrophils. In order to better show the effects, we used four different doses (from 50 μg to 400 μg). Our results show clear dose dependency, but only in sufficiently active glucans. We found no activity at all in some glucans (sample #13), and others (e.g., #4, #7 and #15) showed activity only in extremely high doses.

Glucans stimulate not only the cellular branch of immune reactions, but also the humoral part. We focused on formation of IL-2 by spleen cells. The production of this cytokine was measured after a 48 h in vitro incubation of cells isolated from PBS- or glucan-injected animals. Since the IL-2 secretion of control mice was always zero, all effects of glucan were statistically significant. The most active glucan was glucan #16, followed by glucans #10, #8, and #9 (Table III). None of the samples, however, reached the effects of positive control (Concanavalin A).

In the next part of our experiment, we focused on the use of glucan as an adjuvant using an experimental model of ovalbumin as an antigen. Individual samples were applied daily. Commonly used Freund's adjuvant was used as a positive control. The results are summarized in Table IV, demonstrating that most glucans stimulated the antibody formation, but glucans #1, #2, #7, #11, and #13 showed insignificant effects. The most active sample was #16 followed by samples #8, #10, and #6.

View this table:

• In this window
 
• In a new window

Table IV.

Effect of glucan supplementation on antibody formation.

View this table:

• In this window
 
• In a new window

Table V.

Effect of glucan supplementation on suppression of lung cancer.

In the last part of our comparative study, we focused on effects of glucans on inhibition of cancer growth. To be sure the effects of these samples reflected their potential anticancer properties, we used two different experimental models. With the first model, using a well-defined Lewis lung carcinoma model, we found that seven samples significantly lowered lung metastases (Table V). With the second, using a breast cancer model, we monitored the changes in tumor weight. Our results showed that the individual glucans differed in their activity towards breast or lung cancer suppression and only samples #3, #8, #10, #12, and #16 were the same samples as in case of lung cancer growth. In all other cases, the effects were either not statistically significant or there were no effects at all (Table VI).

View this table:

• In this window
 
• In a new window

Table VI.

Effect of glucan supplementation on mammary carcinoma.

View this table:

• In this window
 
• In a new window

Table VII.

Effect of glucan supplementation on weight of some organs and primary tumors in melanoma-treated mice.

Administration of melanoma cells resulted in a significant weight increase of individual organs such as liver, lung, or spleen (Table VII). Six glucans managed to lower the weight of liver and two of those were also active in the lung. However, none of tested samples had any effect on spleen weight. Five samples successfully lowered the weight of tumors; the most active samples were #8 and #16.

Previous SectionNext Section

Discussion

Glucans are natural polysaccharides consisting of linked glucose molecules. In nature, glucans form a major structural component of the cell wall of numerous organisms such as fungi, bacteria, and yeasts. In addition, glucan can be found in plants; e.g., oat and barley contain glucan as a part of endosperm.

Polysaccharides such as glucans have been studied for almost a century. Almost 80 years ago, Shear and coworkers isolated from the culture of Serratia marcescens a substance causing necrosis of tumors (19). Due to the justified distrust of bacterial sources of polysaccharides, attention gradually shifts to much less dangerous microorganisms, first of all to yeasts. Their intact cells could be, of course, also pyrogenic (20). This pyrogenicity, given mostly by contaminating proteins, is negligible compared to the other effects. Pure isolated polysaccharides are apyrogenic and their biological effects have nothing to do with it, supporting the need for use highly purified glucans. Authors seeking more information on pyrotherapy and polysaccharides should see a recent review by Novak and Vetvicka (21).

Due to the uncertainty of using lipopolysaccharide, our attention focused on zymosan, but even that was not completely without problems. Even though zymosan was able to significantly stimulate nonspecific immune response, it was not clear which of its components was responsible for that activity. Zymosan is not a pure polysaccharide but rather a crude insoluble product, containing about 50% of β-glucan and also around 17% of mannan, 14% of a protein, and some impurities (22). Numerous subsequent studies demonstrated that the active component, responsible for the primary effect of zymosan, is branched polysaccharide β(1-3),β(1-6)-D-glucan (23). Since that time, glucans have become the most studied natural immunomodulators and, due to the many ongoing human clinical trials, have a very strong chance of becoming an officially approved drug in Western medicine.

Despite tens of thousands published papers on biological activities of glucan, it is often difficult to compare the effects as the majority of authors used glucans differing in source, size, or physicochemical properties. Despite numerous interesting reviews summarizing the current knowledge of glucan activities (24-27), the best compare individual glucans against each other using identical experimental designs. In our previous studies, we directly compared over 50 individual glucans (12-16, 18). However, the number of commercially available glucans has multiplied in many countries since, prompting us to compare the new batch of available glucans with glucan #300, which consistently showed the highest activities in the previous studies. In the present study, we used some of the same activities (i.e., phagocytosis, IL-2 production, and antibody response) and added effects on three different types of cancer, as glucan is already used in cancer treatment (11) and most ongoing clinical trials are currently focused on the anti-cancer activities of glucan.

Phagocytosis is often the first test of glucan activities, as glucans were originally considered to be nonspecific stimulators of innate immunity. Phagocytosis is usually increased by glucan supplementation, and the true glucan effects are manifested viareceptor-specific interaction (28). Like in previous studies, we employed synthetic 2-hydroxyethyl methacrylate microparticles known for their minimal nonspecific adhesion to the cell membrane (17), thus limiting false positivity. Our results showed that one-half of the tested samples had no activity at the common dose of 100 μg and one sample had no activity even at the highest dose of 400 μg. On the other hand, the best glucans showed statistically significant activity even at the lowest dose.

Immunostimulators in general and glucans in particular stimulate secretion of various cytokines such as IFN-γ, IL-1, IL-2, and TNF-α (29, 30, 31). In our study, we measured the production of IL-2 by spleen cells. Without any stimulation, the release of IL-2 by these cells is zero, therefore all samples showed significant stimulation (Glucan #300 showing the highest effects). Concanavalin A, serving as a positive control, had even stronger effects.

After overcoming the theory that glucans are only nonspecific stimulators of defense reaction, the common dogma stated that they act on cellular immunity only. Lately, attention is beginning to focus on possible effects on humoral immunity (32), and glucans are now considered to have important potential as a part of vaccines. Our results further confirm‎ that high quality glucans will stimulate antibody response, which, together with the findings of potentiation of the effect of anti-cancer monoclonal antibodies (33), led us to focus on cancer.

Glucan effects on cancer inhibition are well established (7, 34, 35), but only rarely somebody tests the same glucans on several different cancer models. We used three different models, breast and lung cancers and melanoma. Our data showed that glucan supplementation significantly reduced both the weight of primary tumors and the number of lung colonies. In our previous study of testing glucan effects on melanoma, we clearly demonstrated that glucan inhibited the damage to blood cells and potentiated the effects of regular chemotherapy. In addition, these effects were manifested via activation of NK cells (36). Many glucans showed the ability to suppress cancer growth, but this activity varied based on cancer model and only glucans #16 and #8 had significant anti-cancer activity in all three models.

In summary, this study is a follow-up of our three previous studies, testing 43 different glucans. From these experiments, we can conclude that on one hand, glucans can have substantial effects on all branches of the immune system, but on the other hand, not all glucans are created equal. Similar to our older comparative studies, we used glucans isolated from yeast, mushroom, algae, and oat. However, no clear correlation between function and other characteristics, such as source or solubility, could be reached. The differences between activities of our commercially available glucans might be an explanation for the sometimes confusing results found in the literature. In all tests employed in our study, Glucan #300 was the most active.

Previous SectionNext Section

Acknowledgements

The Authors are grateful to Ms. Tracey Bender for her editorial help.

Previous SectionNext Section

Footnotes

• This article is freely accessible online.

• Conflicts of Interest

  No conflicts of interests exist for the Authors.

• Received December 11, 2017.
• Revision received December 25, 2017.
• Accepted December 29, 2017.

• Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Previous Section

 

References

1. ↵
    

   1. Novak M, 
   2. Vetvicka V

   : Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action. J Immunotoxicol 5(1): 47-57, 2008. 

   CrossRefMedlineGoogle Scholar
2. ↵
    

   1. Wursch P, 
   2. Pi-Sunyer FX

   : The role of viscous soluble fiber in the metabolic control of diabetes. A review with special emphasis on cereals rich in beta-glucan. Diabetes Care 20(11): 1774-1780, 1997. 

   Abstract/FREE Full Text
3. ↵
    

   1. Browder W, 
   2. Williams D, 
   3. Lucore P, 
   4. Pretus H, 
   5. Jones E, 
   6. McNamee R

   : Effect of enhanced macrophage function on early wound healing. Surgery 104(2): 224-230, 1988. 

   MedlineGoogle Scholar
4. ↵
    

   1. Vetvicka V, 
   2. Vetvickova J

   : Anti-stress action of an orally-given combination of resveratrol, beta-glucan, and vitamin c. Molecules 19(9): 13724-13734, 2014.

   Google Scholar
5. ↵
    

   1. Vetvicka V, 
   2. Vetvickova J

   : B-glucan attenuates chronic fatique syndrome in murine model. J Nat Sci 1: e112, 2015. 

   Google Scholar
6. ↵
    

   1. Braaten JT, 
   2. Wood PJ, 
   3. Scott FW, 
   4. Wolynetz MS, 
   5. Lowe MK, 
   6. Bradley-White P, 
   7. Collins MW

   : Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr 48(7): 465-474, 1994. 

   MedlineGoogle Scholar
7. ↵
    

   1. Sima P, 
   2. Vannucci L, 
   3. Vetvicka V

   : Glucan and cancer: Historical prospective. Canc Transl Med 1(6): 209-214, 2015. 

   Google Scholar
8. ↵
    

   1. Kushner BH, 
   2. Cheung IY, 
   3. Modak S, 
   4. Kramer K, 
   5. Ragupathi G, 
   6. Cheung NK

   : Phase i trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res 20(5): 1375-1382, 2014. 

   Abstract/FREE Full Text
9. ↵
    

   1. Richter J, 
   2. Svozil V, 
   3. Kral V, 
   4. Rajnohova Dobiasova L, 
   5. Stiborova I, 
   6. Vetvicka V

   : Clinical trials of yeast-derived beta-(1,3) glucan in children: Effects on innate immunity. Ann Transl Med 2(2): 15-20, 2014. 

   Google Scholar
10. ↵
     

    1. Vetvicka V, 
    2. Richter J, 
    3. Svozil V, 
    4. Rajnohova Dobiasova L, 
    5. Kral V

    : Placebo-driven clinical trials of Transfer Point glucan #300 in children with chronic respiratory problems: Antibody production. Am J Immunol 9(2): 43-47, 2013. 

    Google Scholar
11. ↵
     

    1. Ina K, 
    2. Kataoka T, 
    3. Ando T

    : The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem 13(5): 681-688, 2013. 

    Google Scholar
12. ↵
     

    1. Vetvicka V, 
    2. Vetvickova J

    : Immunostimulating properties of two different β-glucans isolated from maitake mushroom (grifola frondosa). JANA 8: 33-39, 2005.

    Google Scholar
13. 1. Vetvicka V, 
    2. Vetvickova J

    : An eval‎uation of the immunological activities of commercially available beta 1, 3 glucans. JANA 10(1): 9-15, 2007.

    Google Scholar
14. 1. Vetvicka V, 
    2. Vetvickova J

    : Physiological effects of different types of beta-glucan. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151(2): 225-231, 2007. 

    CrossRefMedlineGoogle Scholar
15. 1. Vetvicka V, 
    2. Vetvickova J

    : A comparison of injected and orally administered beta glucans. JANA 11(1): 42-49, 2008. 

    Google Scholar
16. ↵
     

    1. Vetvicka V, 
    2. Vetvickova J

    : Comparison of immunological effects of commercially available β-glucans Appl Sci Rep 1: 1-7, 2014. 

    Google Scholar
17. ↵
     

    1. Vetvicka V, 
    2. Fornusek L, 
    3. Kopecek J, 
    4. Kaminkova J, 
    5. Kasparek L, 
    6. Vranova M

    : Phagocytosis of human blood leukocytes: A simple micromethod. Immunol Lett5(2): 97-100, 1982. 

    CrossRefMedlineGoogle Scholar
18. ↵
     

    1. Vetvicka V, 
    2. Vetvickova J

    : B1,3-glucan: Silver bullet or hot air? Open Glycoscience3: 1-6, 2010. 

    Google Scholar
19. ↵
     

    1. Shear MJ, 
    2. Turner FC, 
    3. Perrault A, 
    4. Shovelton T

    : Chemical treatment of tumors. V. Isolation of the hemorrhage–producing fraction from serratia marcescens (bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 4(1): 81-97, 1943. 

    CrossRefGoogle Scholar
20. ↵
     

    1. Kobayashi GS, 
    2. Friedman L

    : Characterization of the pyrogenicity of candida albicans, saccharomyces cerevisiae, and cryptococcus neoformans. J Bacteriol 88: 660-666, 1964. 

    Abstract/FREE Full Text
21. ↵
     

    1. Novak M, 
    2. Vetvicka V

    : From hyperthermia to immunomodulating polysaccharides. Am J Immunol 13(1): 11-18, 2017. 

    Google Scholar
22. ↵
     

    1. Di Carlo FJ, 
    2. Fiore JV

    : On the composition of zymosan. Science 127(3301): 756-757, 1958. 

    FREE Full Text
23. ↵
     

    1. Riggi SJ, 
    2. Di Luzio NR

    : Identification of a reticuloendothelial stimulating agent in zymosan. Am J Physiol 200: 297-300, 1961. 

    Google Scholar
24. ↵
     

    1. de Oliveira Silva V, 
    2. Oliveira de Moura N, 
    3. Rodrigues de Oliveira LJ, 
    4. Peconick AP, 
    5. Pereira LJ

    : Promising effects of beta-glucans on metabolism and on the immune responses: Review article. Am J Immunol 13(1): 62-72, 2017. 

    Google Scholar
25. 1. Meng X, 
    2. Liang H, 
    3. Luo L

    : Antitumor polysaccharides from mushrooms: A review on the structural characteristics, antitumor mechanisms and immunomodulating activities. Carbohydr Res 424: 30-41, 2016. 

    Google Scholar
26. 1. Vannucci L, 
    2. Krizan J, 
    3. Sima P, 
    4. Stakheev D, 
    5. Caja F, 
    6. Rajsiglova L, 
    7. Horak V, 
    8. Saieh M

    : Immunostimulatory properties and antitumor activities of glucans (review). Int J Oncol 43(2): 357-364, 2013. 

    MedlineGoogle Scholar
27. ↵
     

    1. Vannucci L, 
    2. Sima P, 
    3. Vetvicka V, 
    4. Krizan J

    : Lentinan properties in anticancer therapy: A review on the last 12-year literature. Am J Immunol 13(1): 50-61, 2017.

    Google Scholar
28. ↵
     

    1. Větvička Vc

    : β-glucans as natural biological response modifiers. Nova Science Publishers, Inc., New York, 2013. 

    Google Scholar
29. ↵
     

    1. Bedirli A, 
    2. Kerem M, 
    3. Pasaoglu H, 
    4. Akyurek N, 
    5. Tezcaner T, 
    6. Elbeg S, 
    7. Memis L, 
    8. Sakrak O

    : Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis. Shock 27(4): 397-401, 2007. 

    CrossRefMedlineGoogle Scholar
30. ↵
     

    1. Chen Y, 
    2. Dong L, 
    3. Weng D, 
    4. Liu F, 
    5. Song L, 
    6. Li C, 
    7. Tang W, 
    8. Chen J

    : 1,3-beta-glucan affects the balance of th1/th2 cytokines by promoting secretion of anti-inflammatory cytokines in vitro. Mol Med Rep 8(2): 708-712, 2013. 

    Google Scholar
31. ↵
     

    1. Jaymen A, 
    2. Nemeikaitre-Ceniene Am Bratchnikov M, 
    3. Grigiskis S, 
    4. Grigas F, 
    5. Jonauskliene I, 
    6. Zubulyte D, 
    7. Mauricas M

    : β-Glucan from Saccharomyces cerevisiae induces IFN-γ production in vivo in BALB/c mice. In Vivo 29(3): 359-363, 2015.

    Abstract/FREE Full Text
32. ↵
     

    1. Vetvicka V, 
    2. Dvorak B, 
    3. Vetvickova J, 
    4. Richter J, 
    5. Krizan J, 
    6. Sima P, 
    7. Yvin JC

    : Orally administered marine (1-->3)-beta-d-glucan phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol 40(4): 291-298, 2007. 

    CrossRefMedlineGoogle Scholar
33. ↵
     

    1. Xiang D, 
    2. Sharma VR, 
    3. Freter CE, 
    4. Yan J

    : Anti-tumor monoclonal antibodies in conjunction with beta-glucans: A novel anti-cancer immunotherapy. Curr Med Chem 19(25): 4298-4305, 2012. 

    CrossRefMedlineGoogle Scholar
34. ↵
     

    1. Demir G, 
    2. Klein HO, 
    3. Mandel-Molinas N, 
    4. Tuzuner N

    : Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7(1): 113-116, 2007. 

    CrossRefMedlineGoogle Scholar
35. ↵
     

    1. Shomori K, 
    2. Yamamoto M, 
    3. Arifuku I, 
    4. Teramachi K, 
    5. Ito H

    : Antitumor effects of a water-soluble extract from maitake (grifola frondosa) on human gastric cancer cell lines. Oncol Rep 22(3): 615-620, 2009. 

    MedlineGoogle Scholar
36. ↵
     

    1. Vetvicka V, 
    2. Vetvickova J

    : Glucan supplementation has strong anti-melanoma effects: Role of NK cells. Anticancer Res 35(10): 5287-5292, 2015.

    Abstract/FREE Full Text